Lauren Sciences LLC awarded second grant for LAUR-401 from Voices Against Brain Cancer
New York, New York, February 7, 2017 — Lauren Sciences LLC, the private New York biotechnology company developing transformative V-Smart™ Nanomedicines for brain diseases, today announced the award of its second grant from Voices Against Brain Cancer (VABC). VABC grant will support Lauren Sciences continued development of LAUR-401, its novel V-Smart™ Nanomedicine for Glioblastoma Multiforme (GBM). Future success of LAUR-401 should provide an effective new treatment for GBM patients.
LAUR-401 is developed with Lauren Sciences breakthrough V-Smart™ nanotechnology platform, to cross blood brain barrier (BBB) and penetrate central nervous system (CNS) by non-invasive administration, designed for GBM, customized to encapsulate and deliver a known non-brain penetrant chemotherapeutic, and engineered to specifically target, and selectively release at, GBM brain tumor cells. Lauren Sciences goal is for LAUR-401 to stop progression of, and reduce or eradicate, GBM in patients.
"We appreciate VABC's recognition and confidence with this second award," said Susan Rosenbaum, J.D., Founder, Chairman and Chief Executive Officer of Lauren Sciences. "VABC's second award confirms LAUR-401's successful development to date, reaffirms LAUR-401's unique ability to overcome the BBB delivery challenge and anticipates LAUR-401 as a potential transformative therapeutic for brain cancer patients. We are also grateful to our GBM medical advisor, Henry S. Friedman, M.D., Deputy Director of The Preston Robert Tisch Brain Tumor Center at Duke."
"A major goal of VABC is to invest in cutting edge developments that can have a monumental impact on the course of brain cancer," said Michael Klipper, Chairman of VABC. "We are excited about the potential of LAUR-401. Many anti-cancer agents have shown potential for GBM, but, since they can neither cross the brain, by existing oral or i.v. administration, nor target GBM cells, they fall short for patients. This challenge represents a critical unmet medical need for brain cancer that LAUR-401 can overcome."
"LAUR-401 has promise as an effective new treatment for GBM patients," said Irwin Hollander, Ph.D., Vice President, Research and Development, Lauren Sciences. "LAUR-401 should be a disease-modifying drug, unlike standard treatments that, in the vast majority of patients, merely delay disease progression. Lauren Sciences goal is clinical validation and approval of LAUR-401."
About V-Smart™ Nanomedicines
V-Smart™ Nanomedicines, proven to encapsulate therapeutic agents, cross blood brain barrier (BBB), target and deliver to sites in brain, selectively release at target sites, be administered systemically, as well as be safe and effective (in animal model, to date), uniquely solve problem that most therapeutic agents, including biologicals, with potential to treat or cure brain diseases, do not cross BBB. V-Smart™ Nanomedicines will significantly improve lives of patients, because they will enable patients to benefit from therapeutic agents whose use is currently unavailable due to inability to cross BBB, poor PK, bioavailability or toxicity issues, required long term and non-invasive treatment, or even where oral administration is preferable.
About Lauren Sciences LLC
Lauren Sciences was founded in New York, where launched business operations in 2012, licensed groundbreaking V-Smart™ platform nanotechnology from Ben-Gurion University in Israel, where launched R&D of innovative V-Smart™ targeted drug delivery platform, followed with development of proprietary pipeline of transformative V-Smart™ targeted therapeutics — V-Smart™ Nanomedicines — for CNS, neurodegenerative, rare/orphan brain diseases, neurodevelopmental/psychiatric disorders, including: GBM, Parkinson's, Neuro-AIDS, ALS, NPC, Alzheimer's, etc. Lauren Sciences has achieved success with its expert leadership team members, renowned international foundation grant awards, world class medical advisors, prestigious U.S. university medical center collaborations, strategic big pharma project plans, proprietary pipeline products in development, patent family portfolio estate, scientific papers published in peer-reviewed journals, posters at scientific meetings, results presented at conferences and features in industry research reports.
About Voices Against Brain Cancer
Voices Against Brain Cancer's (VABC) mission is to find a cure for brain cancer and brain tumors by advancing scientific research, increasing awareness, creating a brain cancer and tumor community, and supporting patients, their families and caregivers afflicted with this devastating disease. Voices Against Brain Cancer is the personal brainchild of a family, and a father who lost their son to brain cancer. VABC has a wide variety of initiatives in motion for brain cancer research, awareness and support. The organization's research grants fund cutting-edge programs that will have a monumental impact on the diagnosis and treatment of brain cancer and brain tumors. For more information, to make a donation, join an event or offer support, please visit: http://www.voicesagainstbraincancer.org.